<DOC>
	<DOC>NCT01838538</DOC>
	<brief_summary>To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab</brief_summary>
	<brief_title>Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed informed consent obtained prior to initiation of any studyspecific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements. Histologically confirmed and documented ovarian cancer with malignant ascites. ECOG(Eastern Cooperative Oncology Group, ECOG) PS 02. Life expectancy of &gt;3 months. No serious inadequate bone marrow function, liver and renal function or significant cardiovascular disease. Known hypersensitivity to any of the study drugs or excipients. Any current anticancer therapy. No evidence of ascites. Key organ dysfunction. Significant cardiovascular disease (e.g. congestive heart failure (CHF), uncontrolled cardiac arrhythmia, angina, heart valve disease, myocardial infarction and refractory hypertension need to be long time controlled by medicine). Nonhealing wound, ulcer or bone fracture. Uncontrolled psychiatric history.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>